<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6908683\results\search\tropicalVirus\results.xml">
  <result pre="doi: 10.1038/s41467-019-13589-1 : Article Maternal vaccination and protective immunity against" exact="Zika" post="virus vertical transmission http://orcid.org/0000-0002-3953-3782ShanChao12XieXuping1LuoHuanle3MuruatoAntonio E.3LiuYang1WakamiyaMaki1LaJun-Ho4ChungJin Mo4WeaverScott C.35678910WangTian3711ShiPei-Yongpeshi@utmb.edu156781112[1], 0000 0001"/>
  <result pre="this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract An important goal of the" exact="Zika" post="virus (ZIKV) vaccine is to prevent a congenital syndrome"/>
  <result pre="of pregnant women, but studies directly evaluating maternal vaccination for" exact="ZIKV" post="are lacking. Here we report maternal vaccination using a"/>
  <result pre="are lacking. Here we report maternal vaccination using a live-attenuated" exact="ZIKV" post="vaccine (3ʹUTR-∆10-LAV) in a pregnant mouse model. Maternal immunization"/>
  <result pre="or offspring behavior. One maternal immunization fully protects dams against" exact="ZIKV" post="infection and in utero transmission. Although neutralizing antibody alone"/>
  <result pre="dams transfer maternal antibodies to pups, which protect neonates against" exact="ZIKV" post="infection. Notably, pregnancy weakens maternal T cell response to"/>
  <result pre="individuals, 3ʹUTR-∆10-LAV may also be considered for maternal vaccination. A" exact="Zika" post="virus vaccine should protect the fetus during pregnancy. Here,"/>
  <result pre="should protect the fetus during pregnancy. Here, using a live-attenuated" exact="Zika" post="vaccine, the authors show that a higher neutralizing antibody"/>
  <result pre="(Center for Information Technology, National Institutes of Health) U19AI142759ShiPei-Yong Introduction" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus that has recently"/>
  <result pre="emerged and caused major epidemics1. The most devastating disease of" exact="ZIKV" post="infection is congenital Zika syndrome, including microcephaly, congenital malformations,"/>
  <result pre="epidemics1. The most devastating disease of ZIKV infection is congenital" exact="Zika" post="syndrome, including microcephaly, congenital malformations, and demise fetuses from"/>
  <result pre="malformations, and demise fetuses from infected pregnant women2,3. In adults," exact="ZIKV" post="infection is associated with Guillain-Barré syndrome (GBS), an autoimmune"/>
  <result pre="One out of seven infants born to mothers with laboratory-confirmed" exact="ZIKV" post="infection during pregnancy has birth defects, most likely due"/>
  <result pre="explosive epidemics led the World Health Organization (WHO) to declare" exact="ZIKV" post="as a Public Health Emergency of International Concern in"/>
  <result pre="Emergency of International Concern in February 2016. Since then, various" exact="ZIKV" post="vaccine platforms have been developed, with the goal to"/>
  <result pre="entered clinical phase I/II trials8–10. We previously developed a live-attenuated" exact="ZIKV" post="vaccine with a 10-nucleotide deletion in the 3ʹUTR of"/>
  <result pre="viral genome (3ʹUTR-∆10-LAV). A single-dose immunization of 3ʹUTR-∆10-LAV protected against" exact="ZIKV" post="infection and in utero transmission in mice and non-human"/>
  <result pre="the above promising progress, a number of important questions about" exact="ZIKV" post="vaccine research remain to be addressed. Could maternal vaccination"/>
  <result pre="and in utero transmission? Does pregnancy affect immune responses to" exact="ZIKV" post="vaccination? Does maternal immunity derived from vaccination during pregnancy"/>
  <result pre="and non-pregnant individuals require different levels of immunity to prevent" exact="ZIKV" post="infections? Is neutralizing antibody alone sufficient to prevent in"/>
  <result pre="critical to guide the clinical development and regulatory approval of" exact="ZIKV" post="vaccines. In this study, we have addressed the above"/>
  <result pre="and fetuses. A single-dose maternal immunization fully protects dams against" exact="ZIKV" post="infection and in utero transmission. Neutralizing antibody alone is"/>
  <result pre="Furthermore, maternal neutralizing antibodies are transferred to offspring to prevent" exact="ZIKV" post="infection. Results Rapid immunity and long-lasting neutralizing antibodies We"/>
  <result pre="pregnant mice were subcutaneously infected with 105 FFU wild-type (WT)" exact="ZIKV" post="or 3ʹUTR-∆10-LAV. At E18.5, the animals were sacrificed and"/>
  <result pre="twelve-week-old pregnant mice were subcutaneously infected with 105 FFU WT" exact="ZIKV" post="(n = 5) and 3′UTR-Δ10-LAV (Δ10; n = 5) at E0.5. Maternal and"/>
  <result pre="of fetuses collected at E18.5 from placebo, Δ10, and WT" exact="ZIKV" post="groups. Scale bar, 5 mm. Viral loads quantified by plaque"/>
  <result pre="spleen (50%), brain (100%), and placenta (100%) from the WT" exact="ZIKV" post="group; in contrast, no infectious virus was found in"/>
  <result pre="(defined by no increase of neutralizing antibody titers after WT" exact="ZIKV" post="challenge) in A129 mice12. Thus, the dose of 105"/>
  <result pre="(Fig. 2b). After subcutaneously challenged with 106 PFU Puerto Rico" exact="ZIKV" post="strain (PRVABC59) at E10.5, the PBS placebo group developed"/>
  <result pre="with the neutralizing antibody titers detected at E10.5 (Fig. 2b)," exact="ZIKV" post="challenge did not increase the maternal neutralizing titers at"/>
  <result pre="for NT50 measurement and subcutaneously challenged with 106 PFU of" exact="ZIKV" post="PRVABC59. Viremia was quantified by at E12.5. Maternal and"/>
  <result pre="well as fetal weight loss (Supplementary Fig. 7c-h). Challenge with" exact="ZIKV" post="PRVABC59 did not significantly boost maternal neutralizing antibody titers"/>
  <result pre="characterize the effect of maternal vaccination on offspring protection against" exact="ZIKV" post="infection. We performed three experiments to address this question"/>
  <result pre="first experiment examined the protection of maternally transferred immunity against" exact="ZIKV" post="infection in pups. Dams subcutaneously immunized with 103 FFU"/>
  <result pre="naïve pups succumbed to challenges as low as 1 PFU" exact="ZIKV" post="(Supplementary Fig. 8). The results demonstrate that maternal antibodies"/>
  <result pre="to pups through placenta and milk) can protect neonates against" exact="ZIKV" post="infection. Fig. 3 Protection of offspring born to dams"/>
  <result pre="2 pups were subcutaneously challenged at one-day-old with 100 PFU" exact="ZIKV" post="PRVABC59 and monitored for survival for 21 days. Group"/>
  <result pre="day 70, these mice were subcutaneously challenged with 106 FFU" exact="ZIKV" post="PRVABC59 and measured for viremia on day 72. b"/>
  <result pre="n = 9). d Survival of pups after challenge with 100 FFU" exact="ZIKV" post="PRVABC59 (Group 2, n = 11 or 12). e Decay kinetics"/>
  <result pre="Fig. 2). After challenging the 70-day-old pups with 106 PFU" exact="ZIKV" post="PRVABC59, 32% of the animals were protected against viremia"/>
  <result pre="that a minimal NT50 of 1/120 is required to prevent" exact="ZIKV" post="infection accompanied by viremia (Fig. 3g). The third experiment"/>
  <result pre="bled for NT50 measurement and subcutaneously challenged with 106 PFU" exact="ZIKV" post="PRVABC59. The pregnant offspring were quantified for viremia at"/>
  <result pre="minimal NT50 titers are required to protect different organs against" exact="ZIKV" post="infection during pregnancy: 1/200, 1/290, 1/290, and 1/430 for"/>
  <result pre="measured for NT50 levels and subcutaneously challenged with 106 PFU" exact="ZIKV" post="PRVABC59. The animals were assayed for viremia at E12.5"/>
  <result pre="The pregnant mice were then subcutaneously challenged with 106 PFU" exact="ZIKV" post="PRVABC59 at E10.5 and measured for viremia at E12.5."/>
  <result pre="mice require distinct levels of neutralizing antibodies to prevent apparent" exact="ZIKV" post="infection. Ten- to twelve-week-old non-pregnant mice were passively transferred"/>
  <result pre="for measuring NT50 titers and subcutaneously challenged with 106 PFU" exact="ZIKV" post="PRVABC59. Viremia was assayed on day 2 (peak viremia"/>
  <result pre="neutralizing antibodies, T cells play an important role in preventing" exact="ZIKV" post="infection and disease19–21. Thus, we examined T cell response"/>
  <result pre="for T cell analysis by culturing splenocytes, stimulating them with" exact="ZIKV" post="or a viral envelope peptide19, and analysis by an"/>
  <result pre="of CD8+ T cell subsets. Splenocytes were stimulated by a" exact="ZIKV" post="E peptide. Cytokines IL-2 (e) and IFN-γ (f) in"/>
  <result pre="Data file. Discussion The feasibility of a safe and efficacious" exact="ZIKV" post="vaccine is supported by the availability of clinically licensed"/>
  <result pre="and dengue). Compared with the licensed flavivirus vaccines, a successful" exact="ZIKV" post="vaccine has to overcome the unique challenge of protecting"/>
  <result pre="it is essential to determine the correlations of protection against" exact="ZIKV" post="infection in non-pregnant individuals as well as against in"/>
  <result pre="in utero transmission in pregnant women. Given the decline of" exact="ZIKV" post="human cases, identifying these parameters has become even more"/>
  <result pre="that neutralizing antibody alone is sufficient to protect against apparent" exact="ZIKV" post="infection as well as in utero transmission in mice."/>
  <result pre="in utero transmission (NT50 ≥ 1/460) than that required to prevent apparent" exact="ZIKV" post="infection in non-pregnant mice (NT50 ≥ 1/130). The requirement of NT50 ≥ 1/460"/>
  <result pre="(Fig. 4). The requirement of NT50 ≥ 1/130 for prevention of apparent" exact="ZIKV" post="infection in non-pregnant mice is in agreement with previous"/>
  <result pre="development of humoral immunity. Besides prevention of in utero transmission," exact="ZIKV" post="vaccine development also has to overcome the challenge of"/>
  <result pre="Recent studies reported that passively transferred DENV-specific antibodies or previous" exact="DENV" post="infection could increase ZIKV pathogenesis in pregnant mice through"/>
  <result pre="passively transferred DENV-specific antibodies or previous DENV infection could increase" exact="ZIKV" post="pathogenesis in pregnant mice through increasing damage to the"/>
  <result pre="are needed to further determine if pre-immunity derived from natural" exact="DENV" post="or other flavivirus infection enhances ZIKV infection and congenital"/>
  <result pre="pre-immunity derived from natural DENV or other flavivirus infection enhances" exact="ZIKV" post="infection and congenital syndromes39. Vaccination with 3ʹUTR-∆10-LAV may mitigate"/>
  <result pre="detected by the current assays. Infection of placenta with WT" exact="ZIKV" post="was recently shown to mediate pregnancy complications42,43, suggesting that"/>
  <result pre="transmission, transferred maternal antibodies to pups, and protected neonates against" exact="ZIKV" post="infection. However, the protection of offspring declined as the"/>
  <result pre="it should be emphasized that an ideal vaccination strategy for" exact="ZIKV" post="is to immunize children before they reach child-bearing age."/>
  <result pre="maternal vaccination and protective immunity for vertical transmission in a" exact="ZIKV" post="pregnant mouse model. Compared with LAVs, other vaccine platforms"/>
  <result pre="mouse model. Compared with LAVs, other vaccine platforms (particularly inactivated" exact="ZIKV" post="vaccine or DNA subunit vaccine) may be more appropriate"/>
  <result pre="pregnant women because of their non-infective nature. Although both inactivated" exact="ZIKV" post="vaccine or DNA subunit vaccine require multiple doses, the"/>
  <result pre="vaccine platforms in parallel to provide complementary options for preventing" exact="ZIKV" post="infection and disease. Finally, caution should be taken when"/>
  <result pre="made to minimize animal suffering. Viruses, antibodies, and cells The" exact="ZIKV" post="Cambodian strain FSS13025 (GenBank number KU955593.1, referred as WT"/>
  <result pre="in text) was produced from an infectious cDNA clone47. The" exact="ZIKV" post="3’UTR-∆10-LAV strain was generated from the FSS13025 infectious cDNA"/>
  <result pre="strain was generated from the FSS13025 infectious cDNA clone12. The" exact="Zika" post="Puerto Rico strain PRVABC59 (GenBank number KU501215) used for"/>
  <result pre="used to measure the neutralizing antibody titer using an mCherry" exact="ZIKV" post="reporter virus11. Supplementary Fig. 11 depicts the construction of"/>
  <result pre="penicillin/streptomycin and then incubated with an equal volume of mCherry" exact="ZIKV" post="reporter virus at 37 °C for 1 h. Antibody-virus complexes were"/>
  <result pre="stage (E0.5). The mice were infected with 105 FFU WT" exact="ZIKV" post="or 3ʹUTR-∆10-LAV by subcutaneous route at E0.5 or E10.5."/>
  <result pre="for 30 min prior to measuring neutralizing antibodies by the mCherry" exact="ZIKV" post="reporter virus as described above. A129 mouse pregnancy efficacy"/>
  <result pre="retro orbital sinus (R.O.), and immediately challenged with 106 PFU" exact="ZIKV" post="PRVABC59 via subcutaneous route. At E12.5, mice were anesthetized"/>
  <result pre="test. All antibody neutralization titers were determined using an mCherry" exact="ZIKV" post="as described above. Behavioral assays Ten- to twelve-week-old A129"/>
  <result pre="and the force evoking such withdrawal was recorded. Virulence of" exact="ZIKV" post="in one-day-old A129 pups To determine the lethal dose"/>
  <result pre="in one-day-old A129 pups To determine the lethal dose of" exact="ZIKV" post="PRVABC59 on one-day-old A129 pups, pups were injected with"/>
  <result pre="pups, pups were injected with 1, 10, or 100 PFU" exact="ZIKV" post="PRVABC59 via subcutaneous route and monitored for morbidity and"/>
  <result pre="morbidity and mortality. To test the maternal antibody protection against" exact="ZIKV" post="infection, one-day-old pups from 3’UTR-∆10-LAV- or PBS-immunized mice were"/>
  <result pre="3’UTR-∆10-LAV- or PBS-immunized mice were inoculated subcutaneously with 100 PFU" exact="ZIKV" post="PRVABC59. The infected pups were monitored for morbidity and"/>
  <result pre="the mice were bled and immediately challenged with 106 PFU" exact="ZIKV" post="PRVABC59 via subcutaneous route. On day 2 post-challenge, the"/>
  <result pre="the mice were bled and immediately challenged with 106 PFU" exact="ZIKV" post="PRVABC59 via subcutaneous route. The mice were bled for"/>
  <result pre="above. Neutralization antibodies in fetal blood were measured using mCherry" exact="ZIKV" post="reporter virus infection assay as described above. Intracellular cytokine"/>
  <result pre="analyses. Approximately 2.5 × 106 splenocytes were stimulated with 105 FFU live" exact="ZIKV" post="(strain FSS13025) for 24 h or 10 mg/mL E peptide (amino"/>
  <result pre="for 24 h or 10 mg/mL E peptide (amino acids 294–302 from" exact="ZIKV" post="polyprotein) for 5 h. Live ZIKV was used as a"/>
  <result pre="peptide (amino acids 294–302 from ZIKV polyprotein) for 5 h. Live" exact="ZIKV" post="was used as a stimulant to measure CD4+ T"/>
  <result pre="were plated in 96-well plates and stimulated with 1.2 × 104 FFU" exact="ZIKV" post="FSS13025 or 10 mg/mL E peptide19 for 3 days. Culture"/>
  <result pre="of Emerging Virus and Arboviruses (WRCEVA) from UTMB for providing" exact="ZIKV" post="PRVABC59 strain and ZIKV-specific hyper-immune ascitic fluid. P.-Y.S. lab"/>
  <result pre="causalityN. Engl. J. Med.201610.1056/NEJMsr160433828029926 4.Cao-LormeauVMet al.Guillain-Barre Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 5.Oehler,"/>
  <result pre="in French Polynesia: a case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 5.Oehler, E. et al." exact="Zika" post="virus infection complicated by Guillain-Barre syndrome—case report, French Polynesia,"/>
  <result pre="Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital" exact="Zika" post="virus infection—U.S. territories and freely associated states, 2018Mmwr. Morb."/>
  <result pre="challengesCell. Host. Microbe201824121710.1016/j.chom.2018.05.02130008291 8.GaudinskiMRet al.Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
  <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
  <result pre="double-blind, placebo-controlled clinical trialsLancet201839156357110.1016/S0140-6736(17)33106-929217375 11.ShanCet al.A single-dose live-attenuated vaccine prevents" exact="Zika" post="virus pregnancy transmission and testis damageNat. Commun.2017867610.1038/s41467-017-00737-828939807 12.ShanCet al.A"/>
  <result pre="virus pregnancy transmission and testis damageNat. Commun.2017867610.1038/s41467-017-00737-828939807 12.ShanCet al.A live-attenuated" exact="Zika" post="virus vaccine candidate induces sterilizing immunity in mouse modelsNat."/>
  <result pre="et al. Treatment of human glioblastoma with a live attenuated" exact="Zika" post="virus vaccine candidate. MBio9, 10.1128/mBio.01683-18 (2018). 14.ZouJet al.A single-dose"/>
  <result pre="vaccine candidate. MBio9, 10.1128/mBio.01683-18 (2018). 14.ZouJet al.A single-dose plasmid-launched live-attenuated" exact="Zika" post="vaccine induces protective immunityEBioMedicine2018369210210.1016/j.ebiom.2018.08.05630201444 15.ChenJet al.Outcomes of congenital Zika"/>
  <result pre="live-attenuated Zika vaccine induces protective immunityEBioMedicine2018369210210.1016/j.ebiom.2018.08.05630201444 15.ChenJet al.Outcomes of congenital" exact="Zika" post="disease depend on timing of infection and maternal-fetal interferon"/>
  <result pre="interferon actionCell Rep.2017211588159910.1016/j.celrep.2017.10.05929117563 16.DengYQet al.Intranasal infection and contact transmission of" exact="Zika" post="virus in guinea pigsNat. Commun.20178164810.1038/s41467-017-01923-429162827 17.FoudaGGMartinezDRSwamyGKPermarSRThe Impact of IgG"/>
  <result pre="and role of the CD8(+) T cell response during primary" exact="Zika" post="virus infection in miceCell. Host. Microbe201721354610.1016/j.chom.2016.12.01028081442 20.GrifoniAet al.Prior Dengue"/>
  <result pre="primary Zika virus infection in miceCell. Host. Microbe201721354610.1016/j.chom.2016.12.01028081442 20.GrifoniAet al.Prior" exact="Dengue" post="virus exposure shapes T cell immunity to Zika virus"/>
  <result pre="20.GrifoniAet al.Prior Dengue virus exposure shapes T cell immunity to" exact="Zika" post="virus in humansJ. Virol.201710.1128/JVI.01469-1728978707 21.WenJet al.Identification of Zika virus"/>
  <result pre="immunity to Zika virus in humansJ. Virol.201710.1128/JVI.01469-1728978707 21.WenJet al.Identification of" exact="Zika" post="virus epitopes reveals immunodominant and protective roles for dengue"/>
  <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 23.LaroccaRAet al.Vaccine protection against Zika virus from"/>
  <result pre="and licensure of Zika vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 23.LaroccaRAet al.Vaccine protection against" exact="Zika" post="virus from BrazilNature201653647447810.1038/nature1895227355570 24.AbbinkPet al.Therapeutic and protective efficacy of"/>
  <result pre="24.AbbinkPet al.Therapeutic and protective efficacy of a dengue antibody against" exact="Zika" post="infection in rhesus monkeysNat. Med.20182472172310.1038/s41591-018-0056-029867228 25.AbbinkPet al.Protective efficacy of"/>
  <result pre="monkeysNat. Med.20182472172310.1038/s41591-018-0056-029867228 25.AbbinkPet al.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysScience20163531129113210.1126/science.aah615727492477 26.EspinosaDet al.Passive transfer of"/>
  <result pre="monkeysScience20163531129113210.1126/science.aah615727492477 26.EspinosaDet al.Passive transfer of immune sera induced by a" exact="Zika" post="virus-like particle vaccine protects AG129 mice against lethal Zika"/>
  <result pre="a Zika virus-like particle vaccine protects AG129 mice against lethal" exact="Zika" post="virus challengeEBioMedicine201827617010.1016/j.ebiom.2017.12.01029269041 27.JamiesonDJTheilerRNRasmussenSAEmerging infections and pregnancyEmerg. Infect. Dis.2006121638164310.3201/eid1211.06015217283611 28.PazosMSperlingRSMoranTMKrausTAThe"/>
  <result pre="future of early infant protectionHum. Vaccines Immunotherapeutics2015112549255510.1080/21645515.2015.1070984 30.BardinaSVet al.Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunityScience201735617518010.1126/science.aal436528360135 31.DejnirattisaiWet al.Dengue virus"/>
  <result pre="pre-existing immunity to dengue virusNat. Commun.201781567410.1038/ncomms1567428643775 33.GeorgeJet al.Prior exposure to" exact="Zika" post="virus significantly enhances peak Dengue-2 Viremia in Rhesus MacaquesSci."/>
  <result pre="Viremia in Rhesus MacaquesSci. Rep.201771049810.1038/s41598-017-10901-128874759 34.BrownJAet al.Dengue virus immunity increases" exact="Zika" post="virus-induced damage during pregnancyImmunity201910.1016/j.immuni.2019.01.00531732166 35.RathoreAPSSaronWAALimTJahanNSt JohnALMaternal immunity and antibodies"/>
  <result pre="JohnALMaternal immunity and antibodies to dengue virus promote infection and" exact="Zika" post="virus-induced microcephaly in fetusesSci. Adv.20195eaav320810.1126/sciadv.aav320830820456 36.CamargosVNet al.In-depth characterization of"/>
  <result pre="virus-induced microcephaly in fetusesSci. Adv.20195eaav320810.1126/sciadv.aav320830820456 36.CamargosVNet al.In-depth characterization of congenital" exact="Zika" post="syndrome in immunocompetent mice: antibody-dependent enhancement and an antiviral"/>
  <result pre="antiviral peptide therapyEBioMedicine20194451652910.1016/j.ebiom.2019.05.01431130472 37.Rodriguez-BarraquerIet al.Impact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic regionScience201936360761010.1126/science.aav661830733412 38.TerzianACBet al.Viral"/>
  <result pre="cytokine response profile does not support antibody-dependent enhancement in dengue-primed" exact="Zika" post="virus-infected patientsClin. Infect. Dis.2017651260126510.1093/cid/cix55829017246 39.RibeiroGSet al.Does immunity after Zika"/>
  <result pre="dengue-primed Zika virus-infected patientsClin. Infect. Dis.2017651260126510.1093/cid/cix55829017246 39.RibeiroGSet al.Does immunity after" exact="Zika" post="virus infection cross-protect against dengueLancet Glob. Health20186e140e14110.1016/S2214-109X(17)30496-529389533 40.HalsteadSBAchieving safe,"/>
  <result pre="cross-protect against dengueLancet Glob. Health20186e140e14110.1016/S2214-109X(17)30496-529389533 40.HalsteadSBAchieving safe, effective, and durable" exact="Zika" post="virus vaccines: lessons from dengueLancet Infect. Dis.201717e378e38210.1016/S1473-3099(17)30362-628711586 41.HalsteadScott B.Which"/>
  <result pre="Zika virus vaccines: lessons from dengueLancet Infect. Dis.201717e378e38210.1016/S1473-3099(17)30362-628711586 41.HalsteadScott B.Which" exact="Dengue" post="Vaccine Approach Is the Most Promising, and Should We"/>
  <result pre="K.FikrigErolKongYongHorvathTamas L.WeatherbeeScottKlimanHarvey J.CoyneCarolyn B.IwasakiAkikoType I interferons instigate fetal demise after" exact="Zika" post="virus infectionScience Immunology2018319eaao168010.1126/sciimmunol.aao168029305462 44.collab: WHO.Vaccines and vaccination against yellow"/>
  <result pre="2012Mmwr-Morbidity Mortal. Wkly. Rep.201362131135 47.ShanCet al.An infectious cDNA clone of" exact="Zika" post="Virus to study viral virulence, mosquito transmission, and antiviral"/>
  <result pre="48.YangYet al.A cDNA clone-launched platform for high-yield production of inactivated" exact="Zika" post="vaccineEBioMedicine20171714515610.1016/j.ebiom.2017.02.00328196656 49.XieXet al.A single-dose live-attenuated Zika virus vaccine with"/>
  <result pre="high-yield production of inactivated Zika vaccineEBioMedicine20171714515610.1016/j.ebiom.2017.02.00328196656 49.XieXet al.A single-dose live-attenuated" exact="Zika" post="virus vaccine with controlled infection rounds that protects against"/>
 </snippets>
</snippetsTree>
